ESC 2026: enlicitide extends oral PCSK9 benefits beyond LDL-C lowering
Enlicitide strengthens its oral PCSK9 profile with substantial LDL-C lowering and additional reductions in Lp(a).
Enlicitide strengthens its oral PCSK9 profile with substantial LDL-C lowering and additional reductions in Lp(a).